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Abstract  
“Analysis Of Presentation, Management And Outcome  Of Chronic 
Calcific Pancreatitis  In A Tertiary Care Center ” 
 Introduction 
Chronic calcific pancreatitis is a commonly encountered disease in South India. The 
presentation of these patients include pain, steatorrhea, diabetes mellitus, UGI bleed due to 
Gastric varices, Ascites, jaundice, pseudocyst and rarely as duodenal obstruction 
Aim and background: 
To analyse the demographics, spectrum of clinical presentation ,indications for surgery, type of 
surgery, intra operative variables peri operative complications and outcomes of surgery. 
Methods 
This is a retrospective  study of 80 cases of Chronic calcific pancreatitis who had surgery in our 
department. The study included the following parameters: Age of presentation, Gender, 
Etiological factors, Chief symptoms, duration of symptoms, various diagnostic modalities used 
for diagnosis of the disease and the different types of complications on presentation. We also 
included the details of preoperative work up we made and the preoperative treatments given. 
Also we made the analysis of the different types of drainage procedures, resection procedures 
and other additional procedures done for the complicated cases. We analysed the intra op and 
post operative complications and also analysed the short term follow up results of the 50 
patients after discharge. This study was done between August 2011- March2014 
Results 
Based on this study we found that this disease is commonly seen in males( 75%), Ethanol 
induced pancreatitis was found to be the predominant cause(72.5%) and common age group is 
between 30-45  years. The commonest presentation in all patients is Pain, 12.5% had diabetes 
mellitus and 7.5% of them had steatorrhea. We encountered following complications on 
evaluation- three patient had pancreatic ascites, three patients had splenic vein thrombosis and 
portal hypertension, seven patients had Pancreatic pseudocyst and ten  patients had jaundice.  
Freys head coring pancreatico jejunostomy was commonly done by us in about 68 patients, one 
of whom had pancreatic pseudocyst underwent cysto gastrostomy, 2 patients with small duct 
disease underwent Izbecki  procedure of making V shaped incision in duct and ten patients 
underwent Lateral pancreatico jejunostomy. Five of them underwent  distal pancreatectomy &  
Splenectomy as additional procedure (3 for splenic vein thrombosis, 1 for pancreatico pleural 
fistula 1 for infected pancreatic necrosis at tail). One patient Choledocho duodenostomy as 
additional procedure. It has been studied that Frey’s Head Coring Pancreatico jejunostomy 
provided better quality of pain relief and quality of life. 
Conclusion  
 This study  enlightens that, freys  procedure done by single layer anastomosis is cost effective, 
less time consuming and showing no difference in terms of post operative complications like 
pancreatic leak  with zero mortality. 
1 
 
INTRODUCTION 
 
                 Chronic pancreatitis (CP) is a progressive inflammatory disorder 
characterized by irreversible destruction of pancreatic parenchyma,associated 
with disabling chronic pain and permanent loss of exocrine and endocrine 
function. Although the disease was first described by Friedr1ich in 1878, there 
is yet incomplete understanding of the pathophysiology and natural history of 
the disease.   
 
                   The management of patients with chronic pancreatitis remains a 
challenge because of the limited understanding of the pathophysiological 
process of the disease, the unpredictability of clinical evo1lution and the 
controversies between diagnostic criteria and therapeutic options. Worldwide 
the main aetiological factor is alcohol abuse, and the most common symptom is 
relentless chronic abdominal pain. 
1
 
 
                  After optimization of symptoms with analgesics and enzyme 
supplementation, patients with persistent symptoms are candidates for invasive 
treatments. Previous studies have shown that surgical treatment of chronic 
pancreatitis reduces pain and subsequent complications, so that patients return 
to their prior work activities as well as improved quality of life.  The  diseases 
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assumes greater significance on account of the fact it affects young men and 
women  in the prime of their lives. 
Historically, the surgical  procedures have been classified into two categories: 
(i) drainage   
(ii) resection.  
In recent decades, procedures combining resection and drainage  have evolved, 
such as the  FREYS procedure. 
The aim of this retrospective study was to describe a 3-year experience using 
Frey’s procedure in a consecutive series of  patients from a single institution. 
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AIMS AND OBJECTIVES 
 
 
To analyse the demographics, spectrum of clinical presentation ,indications for 
surgery, type of surgery, intra operative variables peri operative complications 
and outcomes of surgery. 
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REVIEW OF LITERATURE 
 INTRODUCTION 
                      Chronic pancreatitis is a progressive inflammatory disorder that 
leads to irreversible destruction of the exocrine and endocrine tissue of the 
pancreas. Fibrotic replacement of the normal pancreas may be associated with 
persistent abdominal pain, the development of exocrine insufficiency, and 
ultimately, diabetes mellitus. Inflammation may lead to local complications, 
including biliary and gastrointestinal obstruction, ascites, mesoportal-splenic 
thrombosis, pseudocyst formation, hemorrhage, and sepsis. Despite multiple 
consensus conferences, there are no uniformly satisfactory criteria for the 
diagnosis, classification, and staging of chronic pancreatitis. In its advanced 
stages, chronic pancreatitis is readily apparent clinically, typically associated 
with pancreatic duct stricture and ductal dilation, stones and diffuse 
parenchymal calcification, and the digestive and metabolic effects of organ 
insufficiency. However, recognition of patients with early and mild disease 
remains a difficult challenge. The absence of a clinically relevant classification 
system for chronic pancreatitis contributes to inconsistencies in the treatment of 
the disease. Treatment decisions, ideally taken after appropriate multidis-
ciplinary input from surgical, endoscopic, and radiologic experts, are better 
made in the context of individual circumstances such as patient symptoms and 
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anatomic findings rather than classification systems based on etiology or 
morphologic severity.      
 DEFINITION: CHRONIC PANCREATITIS 
              . Chronic pancreatitis generally refers to an ongoing inflammatory and 
fibrosing disorder characterized by irreversible morphologic changes, 
progressive and permanent loss of exocrine and endocrine function, and a 
clinical pattern of either recurrent acute exacerbation or persistent pain. In 
reality, however, acute and chronic pancreatitis represent more of a spectrum of 
inflammatory and fibrosing conditions of the pancreas than the two dichotomous 
terms would otherwise imply. Recurrent episodes (or even a single episode) of 
acute pancreatitis may lead to chronic changes within the pancreas, although the 
timing and extent to which such changes merit a change in nomenclature to 
chronic pancreatitis is somewhat arbitrary. The histopathologic changes of 
chronic pancreatitis comprise fibrosis, a reduced number of acinar cells and 
islets of Langerhans, and development of strictures and dilation of pancreatic 
ducts as well as calcium calculi (pancreatic duct stones). The 
morphologic/structural changes of chronic pancreatitis can occur years before 
any clinical symptoms are present. One hypothesis envisions the activation of 
pancreatic stellate cells, which induce desmoplasia, as the key pathogenetic 
"switch" that leads to the transition to chronic pancreatitis
1
. 
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          Efforts to establish consensus for uniform terminology of pancreatitis 
began with an international conference held in Marseille in 1963, during which 
participants agreed that acute pancreatitis should refer to acute organ 
inflammation characterized by interstitial edema, peri-pancreatic fat necrosis, 
and hemorrhage, which resolves if the primary cause or risk factor is removed. 
Chronic pancreatitis was distinguished by irreversible focal, seg-mental, or 
diffuse destruction of the exocrine tissue along with dilation or focal strictures of 
the main pancreatic duct. However, these definitions failed to address the 
functional or clinical dimensions of acute or chronic pancreatitis. At a second 
meeting in Marseille held in 1984 
23
, the  Chronic pancreatitis was subclassified 
as chronic pancreatitis with focal or segmental or diffuse fibrosis, and chronic 
pancreatitis with or without stones, and obstructive chronic pancreatitis was 
listed as a distinct form. Patients with chronic pancreatitis present with recurrent 
episodes of pain or with painless progressive loss of exocrine or endocrine 
insufficiency. To help define changes associated with clinical risk factors, a 
1988 meeting in Rome added the morphologic distinction of chronic calcifying 
pancreatitis that is characterized by intraductal calcifications and protein plugs, 
and chronic inflammatory pancreatitis that is characterized by dense infiltration 
of mononuclear inflammatory cells 
4
. A consensus conference in Cambridge in 
1984 defined the distinction between acute and chronic pancreatitis as the 
reversibility of the morphologic and functional changes of inflammation
5.
 The 
Cambridge meeting proposed a classification system of chronic pancreatitis 
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based on radiographic findings on endoscopic retrograde 
cholangiopancreatography (ERCP) and ultrasonography (US) or computed 
tomography (CT). Criteria for chronic pancreatitis from the Japan Pancreas 
Society focused on findings from an array of diagnostic approaches including 
US, CT, ERCP, secretin stimulation, and histologic examination of pancreatic 
tissue. The presence of certain criteria such as pancreatic stones on CT or US is 
considered definitive evidence of chronic pancreatitis, whereas others such as 
pancreatic deformity with irregular contour are considered only probable or 
possible evidence in support of the disease 
10
. 
RISK FACTORS 
The pathogenesis of chronic pancreatitis remains poorly understood. Most 
hypotheses are more associative and speculative than mechanistic. An 
association between alcohol and acute and chronic pancreatitis has been noted 
for over half a century. Sarles et al demonstrated that the relative risk of chronic 
pancreatitis increases directly with mean daily alcohol consumption
4.
 However, 
even relatively moderate alcohol intake can cause chronic pancreatitis, and the 
duration of alcohol consumption can be relatively short before the onset of 
disease. In alcohol-induced acute pancreatitis, it has been postulated that by-
products of alcohol metabolism induce acinar cell injury, which produces 
pancreatic enzyme (trypsin, chymotrypsin, and phospholipase A) activation and 
local tissue damage by autodigestion and recruitment of inflammatory cells. In 
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chronic pancreatitis, alcohol is thought to increase the protein concentration in 
pancreatic juice, which causes intraductal calcium stone formation, ductal 
epithelial ulceration, inflammation, and fibrosis. Yet it is only a small percentage 
(5% to 10%) of alcoholics that develop pancreatic disease, suggesting that 
alcohol is more of a risk factor than a causative agent for pancreatitis in patients 
who are susceptible for various unknown or poorly defined reasons. Different 
disease processes causing similar-appearing injury to the pancreas may follow 
different clinical courses. Thus, rather than classifying pancreatitis based on the 
presumed causative agent, Whitcomb et al proposed a system to classify risk 
factors that may interact to predispose an individual patient to produce 
pancreatitis.
7
 According to this framework, risk factors are grouped as 
Toxic/Metabolic, Idiopathic, Genetic, Autoimmune, Recurrent Acute, and 
Obstructive 
 
TOXIC/METABOLIC 
Almost 70% of chronic pancreatitis cases are associated with chronic alcoholic 
intake in Western countries.
8
 The prevalence is significantly higher in men 
compared with women. Tobacco use is associated with the early presentation of 
alcoholic chronic pancreatitis and is associated with the presentation of 
calcifications and the development of diabetes. It is unknown whether tobacco 
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initiates the disease
9
; however, tobacco is thought to potentiate the progression 
of chronic pancreatitis. In a preclinical model, investigators demonstrated that 
tobacco exposure increases the risk of pancreatic cancer in chronic pancreatitis 
patients.
10
 Hyperparathyroidism and hyper-calcemia are also associated with 
chronic pancreatitis. Pancreatitis has been reported to be the first manifestation 
of patients with multiple endocrine neoplasia 2A (MEN2A). Patients with 
chronic renal failure have a higher risk of chronic pancreatitis. Certain 
medications, including statins, steroids, oral contraceptives, and inter-feron, as 
well as clinical hyperlipidemia can be associated with chronic pancreatitis, but 
they are more often associated with acute or recurrent acute pancreatitis in high-
risk patients, including the elderly and patients with cancer. 
 IDIOPATHIC 
                            Historically, no environmental or metabolic risk factor can be 
identified in approximately 20% of patients who are therefore categorized as 
having idiopathic acute, recurrent acute, or chronic pancreatitis. Patients with 
idiopathic disease typically fall into a bimodal age distribution, presenting either 
between the ages of 10 and 20 or after age 50 years. However, many of these 
patients are increasingly recognized to have underlying genetic mutations and 
polymorphisms and may be more appropriately recategorized into the genetic 
subgroup. 
10 
 
 
GENE MUTATIONS 
Under physiologic conditions, pancreatic enzyme activation  is strictly 
controlled. Mutations in proteins that regulate this activation increase the risk of 
chronic pancreatitis. Mutations  in the cationic trypsinogen gene (also known as 
protease serine 1 [PRSS1] gene) are common in hereditary chronic pancreatitis. 
PRSS1 is located in chromosome 7 and regulates trypsinogen production; 
mutations in this gene are associated with intraacinar trypsinogen 
activation.PRSS1mutations have been documented inhereditary pancreatitis but 
are uncommon in other forms of chronic pancreatitis. 
SPINK-1 is a peptide secreted by acinar cells that regulates the premature 
activation of trypsinogen. Because SPINK1 mutations are present in 1% to 2% 
of healthy patients ,but the prevalence of chronic pancreatitis is much lower, it 
has been hypothesized that SPINK1 mutations are not enough to trigger 
pancreatic inflammation. However, they lower the threshold to develop it and 
influence the severity of the disease. SPINK1 mutations are more prevalent in 
alcoholic, hereditary, and idiopathic pancreatitis. 
The secretion of bicarbonate and chloride in respiratory and pancreatic 
secretions is regulated by the CFTR gene. CFTR mutations affect the normal 
secretion of bicarbonate, decrease pancreatic juice volume, and augment the 
concentration of pancreatic enzymes inside the pancreatic duct. Homozygous 
11 
 
CTFR mutation result in cystic fibrosis; heterozygous mild mutations 
predispose to pancreatic exocrine insufficienc and chronic pancreatitis. 
The prevalence of CFTR gene mutations is higher in patients with alcoholic, 
idiopathic, and hereditary pancreatitis as compared with the general population 
AUTOIMMUNE 
 
Autoimmune pancreatitis, also known as lymphoplasma- cytic sclerosing 
pancreatitis, is a rare cause (1%) of chronic pancreatitis.
21
 Gland enlargement, 
diffuse duct narrowing, and stenosis of the intrapancreatic portion of the bile 
duct characterize the disease. Histologic examination of the tissue demonstrates 
pancreas parenchyma infiltrated by both CD4+ and CD8+ lymphocytes and 
IgG4 plasma cells, with interstitial fibrosis and acinar cell atrophy. Patients with 
autoimmune pancreatitis have antibodies directed against a peptide that is 
homologous with the sequence of the plasminogen-binding protein (PBP) of 
Helicobacter pylori and with the ubiquitin-protein ligase E3 component n-
recognin 2 which is expressed in the acinar cells of the pancreas.
22
 Autoimmune 
pancreatitis can be associated with other autoimmune diseases including 
Sjogren syndrome, primary sclerosing cholangitis (PSC), and inflammatory 
bowel disease. Primary treatment for autoimmune pancreatitis is steroid treat-
ment. Focal inflammation seen with this disease can often mimic a pancreatic 
mass, which may be difficult to differentiate from a pancreatic malignancy on 
imaging studies. 
12 
 
RECURRENT ACUTE 
 
Recurrent episodes of acute pancreatitis of any etiology can cause chronic 
pancreatitis. This mechanism is poorly understood but likely involves the 
accumulated effects of postinflammatory scarring and necrosis as well as the 
priming of pancreatic stellate cells to induce fibrosis. In addition, radiation and 
ischemia may contribute to irreversible histopathologic changes and 
inflammation characteristic of chronic pancreatitis. 
 
 OBSTRUCTION 
 Obstructive pancreatitis can be congenital, functional, or acquired. Causes of 
pancreatic obstruction include pancreatic or ampullary tumors, and postinjury 
pancreatic duct fibrosis. Elevated basal pressures at the sphincter of Oddi are 
thought by some to lead to relative outflow obstruction from the proximal duct 
and thereby contribute to pancreatitis, although direct evidence for this 
hypothesis is lacking and no convincing mechanism for progression to chronic 
disease has been proposed. Patients may also have anatomic variations in the 
pancreatic ductal system that predispose for obstruction, most notably pancreas 
divisum. Pancreas divisum occurs when the ventral and dorsal aspects of the 
pancreatic ducts fail to fuse during development and, consequently, the drainage 
of the pancreatic body and tail occurs through the dorsal duct and the minor 
papilla. Insufficient caliber of the dorsal duct is thought to induce relative 
13 
 
obstruction to outflow that could lead to pancreatitis. However, the vast 
majority of patients with pancreas divisum are asymptomatic; thus, the 
anatomic variation may predispose to pancreatitis in combination with other risk 
factors rather than initiating pancreatitis directly. 
 
CLINICAL MANIFESTATIONS   
                   The most common symptom of chronic pancreatitis is abdominal 
pain (90%), although the pattern of pain is highly variable. In some patients, 
particularly early in the course of the disease, pain may be a minor feature. The 
pain may be episodic and minimal or absent in between acute exacerbations, but 
it often is noted to gradually become more constant. In late phases of the 
disease, pain may disappear ("burnout"), a transition that is often associated 
with the development of diabetes and exocrine insufficiency. The pain is most 
frequently localized to the epigastrium, often radiates to the back, and is 
typically associated with nausea and vomiting. Overall, the course of chronic 
pancreatitis is highly unpredictable and variable. Because eating can exacerbate 
pain, patients may avoid regular meals, leading to weight loss and malnutrition. 
Between 4% and 30% of patients have significant exocrine insufficiency and 
report bloating, flatulence, or steatorrhea (foul smelling, oily, and loose stools). 
Malabsorption leads to weight loss and deficiencies in micronutrients, 
especially fat-soluble vitamins A, D, and E. Endocrine insufficiency or diabetes 
mellitus develops later in the course of the disease, typically when 90% of the 
14 
 
parenchyma is replaced by fibrosis. Diabetes develops more often in those 
patients with alcohol-associated chronic calcifying pancreatitis than in 
hereditary forms of the disease.  
 
EXTRAPANCREATIC COMPLICATIONS OF CHRONIC PANCREATITIS 
 
A subset of patients develops symptoms of gastrointestinal and biliary 
obstruction. Duodenal, colonic, and bile duct obstruction can occur as a result of 
significant fibro-sis of the head of the pancreas or the development of large 
pseudocysts (Figure 89-1). The incidence of biliary obstruction is approximately 
3% to 23% among patient diagnosed with chronic pancreatitis, and is even 
higher (15% to 60%) among patients who require surgery.24 The incidence of 
duodenal obstruction/stenosis is 2% in all patients, and again is higher (12%) in 
patients who require operative therapy. The majority of patients with splenic 
vein thrombosis are asymptomatic; the incidence of thrombosis varies anywhere 
from 4% to 45% depending on the population surveyed, but very few patients 
present with gastric variceal bleeding.
25,26
 
 
Epidemiologic and preclinical studies demonstrate that chronic pancreatitis is 
associated with the development of pancreatic cancer. Lowenfels et al presented 
a multicenter historical cohort study of 2015 patients with chronic pancreatitis 
followed for at least 2 years.
27
 The standardized incidence risk ratio for the 
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development of pancreatic cancer was 16.5 and 14.4 at 2 and 5 years' followup, 
respectively, for the risk of developing pancreatic cancer. The incidence of 
pancreatic cancer was equally high in patients who presented with pancreatitis 
associated with chronic alcohol use and those with other risk factors.  
 
MECHANISM OF PAIN IN CHRONIC PANCREATITIS 
 
A number of mechanisms have been proposed to account for the pain of chronic 
pancreatitis.  Obstruction of the main pancreatic duct in some circumstances is 
thought to lead to increased ductal pressure (that may in turn be transmitted to 
secondary ducts and the surrounding parenchyma), leading to pain through 
stretch-activated neural pathways. Ductal obstruction may also induce 
missorting and mistargeted basolateral secretion of pancreatic enzymes, 
triggering protease-activated nociceptive pathways. Relief of main duct 
obstruction via decompressive surgical procedures   is often effective treatment 
for pain in these circumstances but is far from universally successful either in 
the short run or in extended followup. Chronic inflammation of the pancreas 
may lead to fibrosis of the peripancreatic capsule and perilobular parenchyma, 
which has been proposed to impair regional and local blood flow, thereby 
producing pain through ischemia and consequent tissue acidosis.
29 
Parenchymal 
fibrosis has also been likened to a "compartment syndrome" of sorts, associated 
with impaired venous drainage.30 Chronic inflammation associated with 
16 
 
chronic pancreatitis may also induce visceral hyperalgesia through neural 
remodeling of local, spinal, or central nociceptive pathways.
31,32
 Superimposed 
on this background of uncertainty regarding the cellular, organ, and systemic 
basis of pain is the confounding influence of narcotic addiction that afflicts 
many affected individuals.  
 
DIAGNOSIS & IMAGING STUDIES 
The diagnosis of chronic pancreatitis may be challenging early in the course of 
the disease because the correlation between symptoms and the structural 
changes seen on imaging studies is poor. The most common CT findings in 
chronic pancreatitis include dilated pancreatic duct (68%), parenchymal atrophy 
(54%), and pancreatic calcifications (50%;). Other findings include 
peripancreatic fluid, focal pancreatic enlargement, biliary duct dilation, and 
irregular pancreatic parenchyma contour. 
CT has a sensitivity of 56% to 95% and a specificity of 85% to 100% for the 
diagnosis of chronic pancreatitis. In addition to establishing the diagnosis, CT is 
particularly useful to assess complications, such as pancreatic duct disruption, 
pseudocysts, portal and splenic vein thrombosis, splenic, and 
pancreaticoduodenal artery pseudoaneurysms.  
 
17 
 
 
                   Fig1      Fig 2     
 
 
 
            
                      Fig3        Fig4  
 
 Fig 1,2,3,4:    contrast and plain CT abdomen showing calcific pancreatitis 
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MRI is a reliable alternative to evaluate patients with chronic pancreatitis. The 
sensitivity for the diagnosis of pancreatic calcifications is lower, but MRI is 
useful to detect changes in the pancreatic parenchyma suggestive of chronic 
inflammation, such as changes in intensity, pancreatic atrophy, and irregularities 
in the contour. In addition, MRCP with secretin injection is particularly useful 
to evaluate intraductal strictures and pancreatic duct disruption. 
Although ERCP was historically considered the gold standard for the diagnosis 
of chronic pancreatitis, the advent of secretin MRCP and EUS have 
significantly decreased its role as a diagnostic test. Current indications include 
patients for whom other diagnostic tests, including CT and MRCP, are 
19 
 
contraindicate or have failed to corroborate the diagnosis. ERCP should be 
considered a therapeutic modalities in patients who develop pancreatic duct 
complications amenable to endoscopic therapy, such as stricture, stone 
,pseudocysts, and biliary stenosis 
EUS has emerged during the past 25 years as the most accurate technique to 
diagnose chronic pancreatitis in patients with minimal-change disease or in the 
early stages. Recently, a panel of endosonographers has defined the criteria 
required to diagnose chronic pancreatitis, known as the Rosemont criteria . 
Histologic evidence of inflammation, atrophy, and fibrosis is the gold standard 
for the diagnosis of chronic pancreatitis; however, current evidence does not 
support the use of EUS-guided FNA or Tru-Cut biopsies to diagnose this 
disease 
 
INTERVENTIONAL THERAPY: ENDOSCOPIC TREATMENT 
 
ERCP is the primary modality for treating symptomatic pancreatic duct 
obstruction with dilation and polyethylene stent placement. A number of 
sessions are usually required because of symptom recurrence. Note that the 
differential diagnosis of pancreatic duct strictures includes pancreatic cancer. 
Only after a thorough evaluation, which includes CT, MRCP, and/or EUS, has 
completely ruled out the possibility of malignancy should endoscopic treatment 
20 
 
be considered. Surgical resection is indicated if any concern of malignancy 
exists. 
Endoscopic stone extraction should be considered for patients with pain and 
pancreatic duct dilation secondary to stones. Extracorporeal shock wave 
lithotripsy followed by therapeutic ERCP may be required for the treatment of 
large impacted stones. The success rate varies from 44% to 77% for this 
technique. 
Biliary obstruction caused by chronic pancreatitis occurs in 10% of patients and 
is best treated with surgical bypass. Temporary relief of the obstruction using 
plastic stents is indicated for patients with cholangitis or for those who are 
severely malnourished. Symptomatic pseudocysts can be drained 
transgastrically or transdudodenally in  selected patients.  
 
SURGICAL TREATMENT 
 
Several factors, including intractable pain, biliary, pancreatic duct or duodenal 
obstruction, pseudo cyst or pseudo aneurysm formation, and the inability to rule 
out malignancy may prompt surgical intervention. The choice of surgical 
procedure depends on the symptoms requiring palliation and the presence or 
absence of pancreatic ductal dilation. In general, patients with a dilated 
pancreatic duct (defined as diameter >7 mm) require a decompressing procedure 
and patients with normal pancreatic duct require a resectional procedure. 
21 
 
RESECTION 
 For patients with focal disease largely confined to the head of the pancreas 
without duct dilation, a Whipple procedure (pancreaticoduodenectomy [PD]) 
was generally the preferred option in olden days .
40
 The procedure involves the 
resection of the head of the pancreas with the distal common bile duct, distal 
stomach, duodenum, and proximal jejunum. Removal of the head of the 
pancreas also addresses bile duct stricture and duodenal obstruction, if present, 
and improves drainage of the upstream proximal (main) pancreatic duct and its 
tributaries. The reconstruction after resection of the Whipple specimen includes 
a two-layered end-to-side pancreatico-jejunostomy , an end-to-side 
hepaticojejunostomy, and a gastrojejunostomy. Pain relief, either complete or 
partial, is usually achieved in approximately 85% of patients. Mortality 
associated with the procedure is generally less than 5% and near zero in 
experienced centers, although the overall rate of postoperative complications is 
relatively high, typically reported between 30% and 40%. Traverso and 
Longmire introduced a pylorus-preserving pancre-aticoduodenectomy (PPPD), 
an operation that was intended to improve functional digestive outcomes and 
quality of life by preserving the physiologic gastric emptying mechanism.
42
 
Long-term followup studies show no meaningful differences in functional 
outcome or maintenance of weight, and PPPD may in fact be associated with a 
slightly higher incidence of early postoperative delayed gastric emptying than 
classic PD. 
22 
 
 
Beger introduced duodenum-preserving pancreatic head resection (DPPHR) as 
an alternative to PD or PPPD.
43
 The procedure includes division of the neck of 
pancreas overlying the confluence of the splenic and superior mesenteric veins 
and removal of the head of the pancreas, leaving a small rim of pancreatic tissue 
along the duodenum. The procedure is completed with end-to-end and side-to-
side Roux-en-Y pancreaticojejunos-tomy (Figure  A). DPPHR maintains 
gastrointestinal and biliary continuity, and achieves similar pain relief
43-45
 and 
improvement in quality of life
46
 as PD. Key steps in the procedure include 
identification and preservation of the posterior branch of the gastroduodenal 
artery and the intrapancreatic portion of the common bile duct. Gloor et al 
described a modification of the DPPHR, known as the Berne procedure, that 
involves excavation of the central portion of the head without formal division of 
the neck.
47
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DECOMPRESSION 
For patients with large duct disease and no focal inflammatory mass, duct-
enteric drainage is the preferred treatment. In 1954, Duval described drainage of 
the tail of the pancreas with a Roux-en-Y limb of jejunum as a procedure for 
chronic pancreatitis. This operation often failed because it did not address 
disease in the proximal pancreas. Puestow and Gillesby introduced a modified 
procedure to drain the entire pancreatic duct along the body and tail of the 
pancreas laterally into a Roux-en-Y limb ofjejunum, which was initially 
described in conjunction with splenectomy and the distal pancreatectomy.
48
 
Partington and Rochelle simplified the Puestow technique by eliminating 
splenectomy and pancreatic resection.
49
 The Puestow procedure or the lateral 
pan-creaticojejunostomy involves a retrocolic side-to-side Roux-en-Y 
pancreaticojejunostomy  
                                          
                                           Partingtons rochalle procedure. 
 
24 
 
HYBRID PROCEDURES 
 
Some patients present with not only large duct disease but also significant 
inflammatory disease within the head of the pancreas, and Puestow-type lateral 
pancreaticoje-junostomy may be insufficient to address potential sources of pain 
within the pancreatic head.  
      
            
Begers procedure                                                    freys procedure 
                                
                                                        Berns procedure 
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Frey introduced a procedure that combines duodenum-sparing resection of the 
pancreatic head, without formal division of the neck of the pancreas, combined 
with longitudinal pancreaticojejunostomy of the dorsal duct.
50
 The Frey 
procedure appears to be an acceptable surgical alternative to achieve durable 
long-term pain relief and decrease opiate dependence in selected patients. In the 
experience of a number of series, 75% or greater success in relief of pain and 
gain of weight was seen after the Frey procedure.
51,52
 For patients with an 
inflammatory head mass but small duct disease, Izbicki introduced a procedure 
that combines excavation of the pancreatic head with a V-shaped longitudinal 
wedge resection, followed by lateral decompressive pancreaticojejunostomy of 
the pancreatic body and tail.
53
 Complete pain relief was reported in 92% of the 
patients, and improvements were seen in physical status, working ability, and 
emotional and social functioning to varying degrees. 
 
TO SUMMARIZE 
 
Chronic pancreatitis results in the progressive and irreversible destruction and 
replacement of the normal pancreatic parenchyma with fibrosis, ultimately 
leading to exocrine and, later, endocrine insufficiency. There is no simple 
unifying mechanism of pathogenesis. Rather, it is the interaction among risk 
factors including environmental exposure, genetic factors, and anatomic 
anomalies that appears to predispose to the development of chronic pancreatitis. 
26 
 
Recognition of chronic pancreatitis in its earliest stages continues to pose a 
challenge despite improvements in diagnostic testing and imaging. Treatment 
decisions should be guided by patient presentation but are hampered by the lack 
of consensus guidelines and by clinician bias. Therapeutic options include risk 
modification, analgesic therapy, diet, endoscopic therapy, and surgical therapy. 
Patients may be best treated in high-volume centers with radiologic, endoscopic, 
and surgical expertise, as well as an ancillary system of social workers, 
dieticians,and  psychologists. 
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                                   MATERIALS AND METHODS 
 
 All   cases of Chronic calcific pancreatitis   managed  between  2011 August  to 
February 2014  in our super specialty institute were analyzed 
 
Age group, sex, occupation, presenting symptoms, co-morbid illness schedule 
type of surgeries performed  & outcome were  analyzed 
 
INCLUSION CRITERIA 
  Patients with classical history and radiological charecteristics of chronic 
calcific pancreatitis 
 
EXCLUSION CRITERIA  
                Patients with chronic calcific pancreatitis who are not willing to 
abstain from alcohol  
                Patients with poor performance status  
 
 
 
INVESTIGATION DETAILS 
Blood investigations  including  CBC, Liver function tests and  RFT, CA 19-9, 
Viral markers. 
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USG abdomen – to look for pseudocyst  
 
Portal Doppler : to look for associated portal hypertension 
 
UGI Scopy: to look for extraneous impression and varices in cases of portal 
hypertension 
 
CECT Abdomen & Pelvis  
                            To look for calcification , head mass, stones in the duct and 
parenchyma and diameter of the head  and associated complications in the form 
of psedocyst and peri splenic collaterls , 
 CT- Angiography -      To look for pseudo aneruysms around pancreas 
 
 
MRCP and MRI-  To look for status of CBD in cases presenting with jaundice 
and cholelithiasis. 
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                                OBSERVATION AND RESULTS 
                                             A total number of 80 patients who were diagnosed 
to have chronic calcific pancreatitis , successfully manged were included in the 
study. The age of the patients varies between 13 to 58 yrs. Most of the patients 
were  in their active earning  period of life  30 to  45 yrs.   (  Tab 1)  
                                      Table-1: Age Groups 
Age groups Number 
 < 15 1 
16-30 15 
31—45 44 
>45 20 
 
Age distribution 
    
  
30 
 
Out of 80 patients , 60 were male and 20 were female . ( Tab2 ) 
 
 
                                                      Tab 2: 
           Sex    Number Percentage 
 Male 60 75% 
Female 20 25% 
                                             
                                                   SEX DISTRIBUTION 
 
 
             
         
 
60 
20 
   Sex distribution 
 Male
Female
31 
 
Regarding the etiology of chronic calcific pancreatitis, alcohol was associated in  
58 patients and 22 patients were considered to be tropical. (Tab3). 
 
                      
                                     Tab 3: 
    Cause Number  Percentage 
    Alcohol 58 72.5% 
     Non – alcohol 22 27.5% 
 
 
                         
                          
 
 
58 
22 
Cause  
    Alcohol
     Non – alcohol 
32 
 
   CLINICAL PRESENTATION: 
 Among the clinical presentations,  all the patients were presented with 
abdominal pain, and the pain score was more than 8 for 68 patients and less than 
8 for 12 patients . In addition to pain, the other clinical presentation were shown 
in ( Tab 4) 
                                                   Tab 4: 
Ugi bleed 3 
Steatorrohea 6 
Diabetes 10 
Pancreatic ascites 3 
Portal hypertension 3 
Jaundice 10 
Pseudocyst 7 
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INVESTIGATIONS: 
All patients underwent 
Blood investigations  including  CBC, Liver function tests and  RFT 
 
USG abdomen – to look for psedocyst  
 
Portal Doppler : to look for associated portal hypertension 
 
3 
6 
10 
3 3 
10 
7 
0
2
4
6
8
10
12
Ugi bleed Steatorrohea Diabetes Pancreatic
ascites
Portal
hypertension
Jaundice Pseudocyst
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UGI Scopy: to look for extraneous impression and varices in cases of portal 
hypertension 
 
CECT Abdomen & Pelvis – to look for calcification , head mass, stones in the 
duct and parenchyma and diameter of the head  and associated complications in 
the form of pseudocyst and peri splenic collaterals 
 
MRI abdomen:  to look for congenital anomalies like pancreas divisum. 
 
Fig A: Plain CT showing calcification 
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FIG:B 
 
 
                                        Fig :C 
                     Fig B, C: MRI showing dilated main pamcreatic duct                
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 We found that , jaundice was evident in 10 patients, 3 patients were presented 
with portal hypertension, one patient was presented with pancreatico pleural 
fistula, one patient was presented with infected pseudocyst in the tail of pancreas 
 
SURGICAL PROCEDURES 
               The patients have been chosen according to the diameter of the duct, 
presence of an inflammatory mass in the head region,and associated with other 
complications in the form pseudocyst, portal hypertension,jaundice. 
All the anastomosis was done using 2”0 prolene as a single layer anastomosis  
Name of the procedure  Number 
Freys procedure 68 
Lateral pancreatico jejunostomy 10 
Izbikis procedure 2 
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             Removal of stones                         head coring& opening of duct   
 
 
 
 
68 
10 2 
SURGICAL PROCEDURES 
Freys procedure
Lateral pancreatico jejunostomy
Izbikis procedure
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                       Creation of roux loop                    Anastomosing the jejunum 
 
 
 
                           Anastomosing the  jejunum with pancreas 
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                                Completed pancrteatico jejunostomy 
          
                                            Removed stones  
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                              OTHER  ASSOCIATED PROCEDURES 
 In addition to the standard  procedures, we have performed other procedures to 
address the other complications. 
Name  of the procedure Number 
Distal pancreatectomy& spleenectomy 5 
Cholecystectomy 2 
Choledochoduodenostomy 1 
Cystogastrostomy 1 
 
 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
5 
2 
1 1 
ADDITIONAL PROCEDURES 
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POST OP COMPLICATIONS 
As like any other surgeries, the complication following the surgical procedures 
for chronic calcific pancreatitis are, 
 Complications Number 
Wound infection 10 
Pulmonary complications 3 
Pancreatic leak 0 
Others( jejuno jejunal intussuception) 1 
 
 
0
2
4
6
8
10
12
Wound infection Pulmonary complications Pancreatic leak Others( jejuno jejunal
intussuception)
Complications 
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FOLLOW UP: 
                        In the immediate follow up period,  all the patients had pain relief  
drastically to the pain score of one and continues to be asymptomatic for a 
period of six months. 
                     Three patients were re admitted with recurrence of pain due to the 
resumption of alcohol. 
                 One patient who underwent lateral pancreatico jejunostomy was 
readmitted with gastric outlet obstruction and GJ was performed, the intra 
operative biopsy showed malignancy. 
                One patient was re admitted with jejuno jejunal intussception and he 
was managed successfully by resection and anastomosis. 
Follow up Pre op Post op 
DM 10 6 
Steatorrohea 6 3 
 
 
43 
 
 
 
 
The average pain score of the patient which was 8 pre operatively has come 
down to 1 in the immediate post op period.  
0
2
4
6
8
Pre op
Post op
Pain score 
Pain score
0
5
10
PRE OP
POST OP
DM 
DM
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Regarding the endocrine functions, the glycemic control was achieved in 6 out 
of 10 patients and tn terms of exocrine function, 3 out of 6 patients were under 
control. 
 
 
 
 
 
 
 
 
0
2
4
6
PRE OP
POST OP
STEATORROHEA 
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DISCUSSION 
                         Surgical intervention for chronic pancreatitis is commonly 
accepted as the most effective therapeutic option for pain control and 
management of complications.The main aim of the surgical treatment of CP is to 
alleviate severe pancreatic pain and to manage pancreatitis-related locoregional 
complications .Although lateral pancreatico jejunostomy(partingtons rochalle) 
which had been practised over 3 decades,  it is clear that this is not a technique 
that solves all problems for patients with CP, especially those when there is no 
pancreatic duct dilatation or the disease is predominantly located in the head of 
the gland. 
                              Many of the patients who underwent LPJ  had   recurrence of 
pain , which  was often attributed to persistence or relapse of the disease  in the 
pancreatic head. So  the symptomatic relief which was the demand by most of 
the patients were  not met.  It is  only the symptomatic relief that we are aiming 
to achieve.The principle of Frey's procedure is to decompress the branch ducts in 
the head of the pancreas, which is considered to be the  pacemaker of the disease 
( "controller of inflammation,") 56 and to core out an inflammatory mass, which 
leads to locoregional complications. The mass in the  pancreatic head region is 
excised almost in its entirety, leaving behind a bridge of pancreatic tissue about 
1cm wide, while a rim of pancreas (5 to 10 mm) remains beside the duodenum 
and on the upper margin of the pancreatic head 53,54 The pancreatic neck above 
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the portal vein and superior mesenteric vein are left intact.  The freys procedure 
is safer and easier to do  by means of coring out of head mass as compared to 
PPPD. Prevention and recurence of complications is lower in PPPD as we 
remove the lower bile duct and duodenum. But  freys procedure itself is 
sufficient for relieving jaundice in many of our cases. But regarding the post 
operative quality of life in terms of  pain relief freys procedure gives much better 
life. Izbicki et al 55 performed a prospective randomized study of 61 patients 
comparing Frey's procedure and PPPD and Long-term Outcomes after Frey's 
Procedure concluded that Frey's procedure achieved equal pain relief and had a 
lower morbidity rate (19%) compared with PPPD (53%) and achieved better 
QOL scores (71 vs. 43) over a 2-year follow-up period. 
                    Our observation and results supports the fact that freys procedure is 
considered to be the best procedure in patients with chronic calcific pancreatitis 
with a head mass. In terms complications in the form jaundice was also could be 
managed successfully with freys procedure itself.    Three patients were 
presented with recurrence of pain due to resumption of alcohol in the post 
operative period were managed with celiac neurolysis and one patient was 
presented with gastric oultlet obstruction  about 6months later was treated  by 
gastrojejunostomy found to have malignancy during the post op period, which 
managed with celiac plexus neurolysis.. The incidence of these complications, 
requiring further treatment, after surgery is not necessarily high, even if alcohol 
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consumption is resumed.  We found that , in our study out of 80 patients 26 
patients were presented with pancreatitis related locoregional complications, 
32.5% which is less as compared to the study  by Neggi et al 15 . 
             Additional procedure had been performed to manage the locoregional 
complications like choledocho dudodenostomy, cystogastrostomy and distal 
pancreatectomy with spleenectomy, none of our patients developed 
complications in relation to the additional procedures ,several articles published 
that they may end up with complications 18,19. 
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CONCLUSIONS 
In our study about 55% of the patients were within the age group of 30-45 which 
is the prime earning period of life thereby limiting the socio economic status of 
the family. 
Males were predominant than females.( 75% Vs25%) 
Ethanol was the prime etiologic factor ( 72.5%) 
Pain was the primary mode of presentation and about 32.5% were presented 
with locoregional complications of panceatitis. 
Endocrine insufficiency was present in about 12.5% among that 7.5% of the 
patients had good glycemic control in immediate post op period. 
Exocrine insufficiency was present in 7.5%  of the patients, of which 3.5% had 
good symptomatic relief. 
The results of the study in our institute,  revealed the fact that the extended 
drainage  procedure with coring out of tissue in the region of the head  as 
proposed by Frey ( resection and drainage) has high effectiveness in the 
treatment of pain , combined with little interference in the disease course 
(endocrine and exocrine function). 
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All the patients in our institute were operated  by   a single layer anastomotic 
technique, using 2” 0 prolene  which is very cost effective, less time consuming 
and showing no difference in terms of post operative complications like 
pancreatic leak. 
 Frey’s procedure should be considered as the primary operation in patients with 
disabling pain as a result of  CP because it is safer, easier and presents less 
morbidity and  zero  mortality than alternative technique if it is performed in a 
high volume center. 
The long‑term results of  pain relief  are in excess of  90% and there may be 
functional benefit in terms of  preservation of  pancreatic function in the long 
term. 
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                                     CASE REPORT FORM 
 
 
Name: 
Age/sex: 
Address: 
Contact Numbers: 
Occupation: 
Body weight: 
 
Personal habits: 
Alcoholic: 
 Duration 
 Type of liquor 
 Amount 
 Manner 
Smoker: 
 Duration 
 Type 
 Number 
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Clinical Features: 
Visual analog scale: Pain score: ( Tick)   
 
 
 
Duration of pain: 
Character of pain: 
 
Past H/o: Any surgery: 
 
Symptoms Tick  Signs  Tick 
Steatorrhea   Thin built  
Diabetes   Splenomegaly  
Diarrhoea   Mass abdomen  
Hematemesis   Ascites  
Melena   Jaundice  
Weight loss     
Jaundice     
 
Diabetes: 
 On Tablets 
 On Insulin 
Clinical examination 
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Investigations 
TC- 
FBS: 
PPBS: 
Hemoglobin- 
Amylase- 
Lipase- 
 
CA 19-9: 
Se albumin 
Bilirubin 
SGOT/SGPT 
PT /INR: 
UGI SCOPY- 
 
PV Doppler- 
 
CECT abdomen- 
 
USG abdomen- 
 
MRCP- 
 
 
 
 
 
 
Final diagnosis: 
1. Tropical pancreatitis 
2. Alcoholic pancreatitis 
3. Anything else 
4. Associate complications: 
5. Diabetic 
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Management: 
 
Surgery done: 
 
Date of Surgery: 
 
 
Procedure in nutshell: 
 
 
 
 
Anastomosis technique:  
 
 
 
 
Any other Important findings Associated: 
 
 
 
Operative time: 
 
Operative blood loss: 
 
Intra Operative transfusion: 
 
Intraop complications: 
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Post Op Events: 
 
Blood transfusion: 
 
Wound infection: 
 
Ryles tube removal: 
Oral started on: 
 
Pain score after 1 week: 
 
Blood sugar after 1 week: 
 
Discharge Post op Day: 
 
Biopsy no; Biopsy report: 
 
 
 
 
 
Follow up: 
 
After 1 month: 
 Pain score 
 Weight gain 
 Diabetes- FBS/ PPBS 
 Any other complaint 
 
After 3 months: 
 Pain score 
 Weight gain 
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 Diabetes- FBS/ PPBS 
 Any other complaint 
 
After 6 months: 
 Pain score 
 Weight gain 
 Diabetes- FBS/ PPBS 
 Any other complaint 
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                                        Information to Participants 
 
Title: -        “ ANALYSIS OF PRESENTATION, MANAGEMENT AND  
OUTCOME  OF CHRONIC CALCIFIC PANCREATITIS  IN A TERTIARY CARE CENTER ” 
 
 
Principal Investigator:  Dr.R.Rajkumar 
Co-Investigator(if any): 
 
Name of Participant: 
 
Site :   
 
You are invited to take part in this research/ study/procedures/tests. The information in this document is 
meant to help you decide whether or not to take part. Please feel free to ask if you have any queries or 
concerns. 
 
What is the purpose of research? 
 
Colorectal cancer is the third most frequent cancer in men and women. Surgery remains the 
mainstay of treatment which alone results in local recurrence in locally advanced tumors. Improved 
staging, introduction of multidisciplinary decision-making, refined surgery and appropriate use 
of preoperative radiotherapy, together with quality assessment by pathology and registries have 
all contributed to substantially lowering rates of local recurrence in rectal cancer from 30% to 
below 10%. Current standard for locally advanced rectal cancer includes preoperative 
chemoradiation followed by surgery. We want to test the efficacy and safety of a new _________ 
(drug / intervention / surgery /procedure/lab test) in this disease/condition.  
 
We have obtained permission from the Institutional Ethics Committee.  
 
The study design 
 
 Prospective and Retrospective study   
 
Study Procedures 
 
The study involves evaluation of Locally advanced Carcinoma Rectum treated with neoadjuvant therapy  
for  which we will need tumor markers, barium enema colonoscopy, CECT Abdomen  & Pelvis. The 
planned scheduled involve visits at _____,_____,____, 
 
 and______(days/ weeks) after your initial visit. You will be required to visit the hospital _______ number 
of times during the study.  
 
At each visit, the study physician will examine you. Some [blood / urine /imaging/clinical examination 
other] tests will be carried out at each visit. [… … ml of blood will be collected at each visit. Blood 
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collection involves prick with a needle and syringe.] These tests are essential to monitor your condition, 
and to assess the safety and efficacy of the treatment given to you. 
In addition, if you notice any physical or mental change(s), you must contact the persons listed at the  
 
end of the document.  
 
You may have to come to the hospital (study site) for examination and investigations apart from your  
 
scheduled visits, if required.  
 
Possible risks to you – If any, Briefly mention  
 
 
 
Possible benefits to you - If any, Briefly mention  
  
 
 
Possible benefits to other people  
 
The results of the research may provide benefits to the society in terms of advancement of medical 
knowledge and/or therapeutic benefit to future patients.  
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical information (personal details, 
results of physical examinations, investigations, and your medical history). By signing this document, you 
will be allowing the research team investigators, other study personnel, sponsors, Institutional Ethics 
Committee and any person or agency required by law like the Drug Controller General of India to view 
your data, if required. 
The information from this study, if published in scientific journals or presented at scientific meetings,  
will not reveal your identity. 
 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect your medical care or your relationship 
with the investigator or the institution. You will be taken care of and you will not loose any benefits to 
which you are entitled.  
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the right to withdraw from this study at 
any time during the course of the study without giving any reasons. However, it is advisable that you talk 
to the research team prior to stopping the treatment/discontinuing of procedures etc. 
 
 
Signature of Investigator                                                                      Signature of Participant   
Date                                                                                                      Date   
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1 26/f ccp Y N Y 6 10 freys 17-01-14 100 2 4 y 3 1 1 1
2 24/f ccp y y y y 8 y 8 freys 6/3/2014 100 3 6 y y 5 1 1 1
3 36/m ccp y y y y 8 y y 7 lpj dp+s 200 3 0 y y 1 1
4 40/m ccp Y Y Y Y 7 Y y 10 freys 11/1/2014 150 3 5 3 1 1 1
5 46/m ccp y y y y 5 cons
6 38/m ccp Y Y Y 8 Y y 11 freys 6/1/2014 120 2 5 3 1 1 1
7 57/f ccp Y Y Y 9 y 10 freys 14-12-13 200 2.5 5 3 1 1 1
8 42/m ccp Y Y Y 9 Y y 9 freys 5/12/2013 150 3 7 3 1 1 1
9 35/m ac.on ch y Y y Y y 5 cons
10 15/m ccp Y Y Y Y 8 Y Y y 9 freys 28-11-13 300 3 6 y 3 1 1 2
11 40/m ccp Y Y Y 9 Y y 10 freys 28-11-13 300 2.5 6 3 1 1 1
12 48/m ccp Y Y Y Y st 8 Y y 10 freys dp+s 23-11-13 200 6 y 3 1 1 1
13 16/f CCP Y Y Y dm 9 y 10 freys 7/11/2013 300 3 6 3 1 1 1
14 42/f CCP Y N Y 8 y 10 freys 31-10-13 100 3 7 3 1 1 1
15 22/f CCP Y Y Y 9 y 10 freys 29-10-13 200 3 7 3 1 1 1
16 36/M CCP Y Y Y Y 9 Y y 10 freys 29-10-13 100 3 6 3 1 1 1
17 42/m ac.on ch y y y y 9 lpj dp+s 28-09-13 300 3 0 pnem 3 1 1 1
18 34/m CCP Y N Y 9 Y y 10 freys 30-09-13 200 3 6 y 3 1 1 2
19 34/m CCP Y Y Y st 7 Y y 10 freys 12/9/2013 300 3 6 4 1 1 1
20 53/m CCP Y Y Y Y 9 Y Y y 11 freys 29-08-13 350 3 6 y 3 1 1 1
21 31/m CCP Y Y Y 7 Y y 12 freys 29-08-13 150 3 7 3 1 1 1
22 30/m CCP Y Y Y Y dm 9 Y Y n 11 LPJ 22-08-13 200 3 7 y 3 1 1 1
23 45/m CCP Y Y y y 9 Y n 11 freys chole 14-08-13 200 3 7 3 1 1 1
24 48/m CCP Y Y Y 9 Y y 10 freys 8/8/2013 100 2.5 7 3 1 1 1
25 45/m CP Y N y Y dm 8 y 10 freys chole 16-08-13 200 2.5 8 3 1 1 1
26 51/m CCP Y Y Y 8 Y y 10 freys 5/8/2013 100 3 7 y 3 1 1 1
27 43/m CCP Y Y Y 9 Y y 11 freys 2/8/2013 150 3 6 3 1 1 2
28 43/m ac.on ch y Y Y y 8 y 8 lpj 4/8/2013 300 0 3 1 1 1
29 44/m CCP Y Y Y st 8 Y y 10 freys 10/7/2013 200 3 6 3 1 1 2
30 48/f CCP Y Y Y 8 y 6 freys 12/7/2013 300 3 6 3 1 1 1
31 41/m CCP Y Y Y 8 Y y 10 LPJ 11/7/2013 200 3 6 pnem 3 1 1 1
32 44/f CCP Y Y Y Y 8 Y y 8 freys 23-05-13 200 3 6 y 3 1 1 1
33 44/m CCP Y Y Y st 8 Y Y y 6 freys 9/5/2013 200 3 7 4 1 1 1
34 48/m CCP Y Y y Y Y 8 Y y 9 freys dp+s 4/5/2013 300 3 7 3 1 1 1
35 24/f CCP Y Y Y Y 9 Y y 9 LPJ 26-04-13 200 3 7 3 1 1 1
36 40/m CCP Y Y Y 8 Y n 9 freys 21-04-13 200 3 7 3 1 1 1
37 58/m CCP Y Y Y dm 9 Y y 9 freys 15-04-13 200 3 6 y 3 1 1 1
38 44/m CCP Y Y Y 8 Y Y y 9 LPJ 7/3/2013 100 3 6 y 3 1 1 1
39 49/m CCP Y N Y y 9 Y y 9 freys 7/3/2013 200 3 6 3 1 1 1
40 35/f CCP Y Y Y Y 9 y 9 freys 28-02-13 100 3 6 3 1 1 1
41 20/f CCP Y N Y 8 y 9 freys 28-02-13 200 3 5 3 1 1 1
42 43/m CCP Y Y Y dm 9 y 9 freys 28-02-13 100 3 5 3 1 1 1
43 36 CCP Y Y Y 8 y 11 freys 28-02-13 200 3 5 3 1 1 1
44 40/m CCP Y Y Y 9 Y y 10 freys 14-02-13 100 3 5 3 1 1 1
45 26/m CCP Y Y Y 9 y 9 LPJ 7/2/2013 200 3 5 3 1 1 1
46 40/m CCP Y Y Y Y Y dm 9 Y Y y 9 freys dp+s 7/2/2013 100 3 4 y y 3 1 1 1
47 22/f CCP Y Y Y 8 y 9 freys 3/1/2013 200 3 4 3 1 1 1
48 52/m CCP Y Y Y 9 Y y 9 freys 27-12-12 100 3 7 pnem 4 1 1 1
49 48/m CCP Y Y Y y dm 7 Y y 9 freys CG 22-12-12 100 3 7 3 1 1 1
50 45/m ccp Y N Y 8 Y y 9 freys 21-12-12 200 3 7 3 1 1 1
51 37/m CCP Y Y Y Y 8 Y y 9 freys 11/12/2012 100 3 7 3 1 1 1
52 26/f CCP Y Y Y 9 y 9 freys 29-11-12 200 3 5 3 1 1 1
53 33/m CCP Y Y Y 8 Y y 3 IZBIKI 29-11-12 200 33 6 3 1 1 1
54 32/m CCP Y Y Y 8 n 9 freys 27-11-12 200 2.5 6 3 1 1 1
55 28/f CCP Y Y Y Y 8 Y y 9 freys 7/10/2012 150 3 7 y 3 1 1 1
56 30/m CCP Y Y Y 8 Y y 10 freys 20-09-12 200 3 6 3 1 1 1
57 42/f CCP Y Y Y Y dm 8 y 11 freys 14-08-12 300 3 6 3 1 1 1
58 34/m CCP Y N Y 8 Y y 11 freys 30-07-12 200 3 7 3 1 1 1
59 36/m CCP Y Y Y 8 Y Y n 10 freys 25-07-12 100 3 7 y 3 1 1 1
60 33/m ccp Y Y Y 8 Y y 9 freys 23-07-12 200 3 6 3 1 1 2
61 58/m ccp Y Y Y st 8 Y y 8 freys 17-07-12 100 3 7 y 3 1 1 1
62 37/m ccp Y Y Y dm 8 Y y 9 freys 16-07-12 200 3 6 jj int 3 1 1 1
63 15/f ccp Y Y Y Y 8 y 9 freys 3/7/2012 100 2.5 7 3 1 1 1
64 30/m ccp Y Y Y Y 9 y 9 freys 14-05-12 200 3 6 3 1 1 1
65 15/f ccp Y Y Y Y 9 Y y 9 freys 3/5/2012 300 3 7 3 1 1 1
66 47/m ccp Y Y Y 9 Y y 9 LPJ 12/7/2012 200 3 6 3 1 1 1
67 25/m ccp Y Y Y st 9 y 9 freys 8/3/2012 100 3 6 y 4 1 1 1
68 48/m ccp Y Y Y 9 Y n 10 freys 6/3/2012 200 3 7 3 1 1 1
69 42/m ccp Y Y Y 9 + Y y 9 freys 6/3/2012 200 3 8 3 1 1 1
70 36/f ccp Y Y Y 9 y 9 freys 23-02-12 300 3 8 3 1 1 1
71 40/m ccp Y Y Y 9 Y y 9 freys 17-02-12 150 3 6 3 1 1 1
72 13/m ccp Y Y Y 9 y 9 freys 24-01-12 200 3 6 3 1 1 1
73 30/m ccp Y Y Y 9 Y y 9 freys 15-12-11 100 3 6 3 1 1 1
74 45/m ccp Y Y Y Y dm 8 Y Y y 3 IZBIKI 19-11-11 150 3 6 3 1 1 1
75 32/m ccp Y Y Y Y 7 Y Y n 10 freys 10/11/2011 200 3 6 y 3 1 1 1
76 30/f ccp Y Y Y 8 y 10 freys 8/11/2011 100 2.5 7 3 1 1 1
77 46/m ccp Y Y y Y Y 8 Y y 9 freys CDD 22/09/11 200 3 7 3 1 1 1
78 34/m ccp Y Y Y 9 Y y 9 freys 6/9/2011 100 3 6 3 1 1 1
79 35/F ccp Y Y Y 9 Y y 9 freys 200 3 6 y 3 1 1 1
80 23/f ccp y y y 8 y lpj 200 3 7 2 1 1 1
intra op surgery doneclinical presentation post op follow up
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52 26/f CCP Y Y Y 9 y 9 freys 29-11-12 200 3 5 3 1 1 1
53 33/m CCP Y Y Y 8 Y y 3 IZBIKI 29-11-12 200 33 6 3 1 1 1
54 32/m CCP Y Y Y 8 n 9 freys 27-11-12 200 2.5 6 3 1 1 1
55 28/f CCP Y Y Y Y 8 Y y 9 freys 7/10/2012 150 3 7 y 3 1 1 1
56 30/m CCP Y Y Y 8 Y y 10 freys 20-09-12 200 3 6 3 1 1 1
57 42/f CCP Y Y Y Y dm 8 y 11 freys 14-08-12 300 3 6 3 1 1 1
58 34/m CCP Y N Y 8 Y y 11 freys 30-07-12 200 3 7 3 1 1 1
59 36/m CCP Y Y Y 8 Y Y n 10 freys 25-07-12 100 3 7 y 3 1 1 1
60 33/m ccp Y Y Y 8 Y y 9 freys 23-07-12 200 3 6 3 1 1 2
61 58/m ccp Y Y Y st 8 Y y 8 freys 17-07-12 100 3 7 y 3 1 1 1
62 37/m ccp Y Y Y dm 8 Y y 9 freys 16-07-12 200 3 6 jj int 3 1 1 1
63 15/f ccp Y Y Y Y 8 y 9 freys 3/7/2012 100 2.5 7 3 1 1 1
64 30/m ccp Y Y Y Y 9 y 9 freys 14-05-12 200 3 6 3 1 1 1
65 15/f ccp Y Y Y Y 9 Y y 9 freys 3/5/2012 300 3 7 3 1 1 1
66 47/m ccp Y Y Y 9 Y y 9 LPJ 12/7/2012 200 3 6 3 1 1 1
67 25/m ccp Y Y Y st 9 y 9 freys 8/3/2012 100 3 6 y 4 1 1 1
68 48/m ccp Y Y Y 9 Y n 10 freys 6/3/2012 200 3 7 3 1 1 1
69 42/m ccp Y Y Y 9 + Y y 9 freys 6/3/2012 200 3 8 3 1 1 1
70 36/f ccp Y Y Y 9 y 9 freys 23-02-12 300 3 8 3 1 1 1
71 40/m ccp Y Y Y 9 Y y 9 freys 17-02-12 150 3 6 3 1 1 1
72 13/m ccp Y Y Y 9 y 9 freys 24-01-12 200 3 6 3 1 1 1
73 30/m ccp Y Y Y 9 Y y 9 freys 15-12-11 100 3 6 3 1 1 1
74 45/m ccp Y Y Y Y dm 8 Y Y y 3 IZBIKI 19-11-11 150 3 6 3 1 1 1
75 32/m ccp Y Y Y Y 7 Y Y n 10 freys 10/11/2011 200 3 6 y 3 1 1 1
76 30/f ccp Y Y Y 8 y 10 freys 8/11/2011 100 2.5 7 3 1 1 1
77 46/m ccp Y Y y Y Y 8 Y y 9 freys CDD 22/09/11 200 3 7 3 1 1 1
78 34/m ccp Y Y Y 9 Y y 9 freys 6/9/2011 100 3 6 3 1 1 1
79 35/F ccp Y Y Y 9 Y y 9 freys 200 3 6 y 3 1 1 1
80 23/f ccp y y y 8 y lpj 200 3 7 2 1 1 1
